2,308.90
-2.64%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hester Biosciences
Its shares trade on NSE under the ticker HESTERBIO.NS. It has been listed since 17 August 1994. In the fiscal year to 31 March 2026, it reported revenue of ₹3.33bn and net income of ₹556.4m. At that date it held total assets of ₹6.78bn and shareholders' equity of ₹3.60bn.
Hester Biosciences Ltd. is a holding company, which engages in the manufacture and trade of poultry vaccines and animal health products. The company is headquartered in Ahmedabad, Gujarat. The firm is engaged in providing vaccines, health products and diagnostic laboratory services. The firm operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Aug 1994
- Employees
- 693
- Website
- hester.in ↗
Leadership
Pay as last reported
- Dr. Bhupendra GandhiNon-Executive Chairman of the Board₹200,000
- Mr. Rajiv GandhiChief Executive Officer, Managing Director, Executive Director₹48.5m
- Mr. Divyesh MaruChief Financial Officer
- Mr. Vinod MaliCompliance Officer, Company Secretary
- Ms. Priya GandhiExecutive Director, since 2021₹4.0m
- Ms. Nina GandhiNon-Executive Director₹300,000
- Mr. Ravin GandhiNon-Executive Director
- Mr. Sanjiv GandhiNon-Executive Director₹200,000
- Mr. Ashok BhadakalNon-Executive Independent Director₹550,000
- Mr. Ameetkumar DesaiNon-Executive Independent Director₹100,000
- Mr. Anil JainNon-Executive Independent Director
- Ms. Sandhya PatelNon-Executive Independent Director₹580,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hester Biosciences Ltd. manufactures poultry vaccines and animal health products in Ahmedabad, India.
- The company offers a wide range of animal healthcare vaccines including Goat Pox and PPR Vaccine.
- Hester Biosciences operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others.
Weaknesses
- Hester Biosciences Ltd. has 693 employees, which may limit scalability in the Health Care sector.
- The company's focus on animal health products may restrict diversification into other healthcare areas.
- Hester Biosciences operates primarily in India, limiting international market reach.
Opportunities
- Expanding Poultry Healthcare products like Inactivated ND IB could increase market share in India.
- Growing demand for Petcare products such as Hestacef CV and Hestaliv presents new revenue streams.
- The Animal Healthcare segment's Goat Pox Vaccine could benefit from rising livestock health needs.
Threats
- Competition from other animal health product manufacturers in the Indian market.
- Regulatory changes in the Health Care sector could impact vaccine approvals.
- Economic downturns may reduce spending on animal health products in India.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.